Valeant: Under Investigation by SEC

The transcript discusses ongoing investigations into a company, highlighting accounting concerns and restated earnings. It mentions the company's debt and potential impact on its ratings. The focus is on how the company plans to manage its debt and grow organically, given constraints on its traditional business model. The transcript also touches on investor expectations and the need for transparency in the investigation's outcome.

What are the potential implications of Valiant not raising drug prices anymore?

What are the expectations from Valiant's upcoming disclosures regarding the investigations?